Discovering, developing and delivering life-changing therapies to treat rare central nervous system disorders.
PDF) Sage Therapeutics-Sitting On The Brink Of CNS Breakthroughs
Breakthrough Agitation Agent; Demi Lovato's Bipolar Misdiagnosis? | MedPage Today
SY Investing on Twitter: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE- 217 showed mean reduction of 12.6 in HAM-D total
sage-10k_20191231.htm
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire
Defensive Strategies For Sage Therapeutics In The Aftermath Of Potential SAGE-547 Regulatory Action (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
sage-10k_20181231.htm
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder - Chemdiv
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
BioWorld
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics surges 70% after depression drug breakthrough
Sage advice: psychiatric drug development is tough | Evaluate
Sage surges after depression drug gets rapid path to approval - PMLiVE
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
